



MEDIA RELEASE
For release October 14, 2010

Innovascreen to Collaborate with the National Cancer Institute to Evaluate Novel Anti-angiogenic Agents

HALIFAX, NOVA SCOTIA, CANADA – October 14th, 2010 -- Innovascreen, Inc., a private biotechnology company focused on the evaluation and development of novel therapeutics in oncology, announces today that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the US National Institute of Health to evaluate a panel of compounds for anti-angiogenic activity using its proprietary *in vivo* angiogenesis assay. Innovascreen's *in vivo* assays are based on the advanced Avian System for Evaluating Therapeutics (ASET), combining a scalable *in vivo* model with non-invasive, intravital imaging to monitor and quantify up to six distinct molecular features in real time. Innovascreen will collaborate with Dr. Enrique Zudaire, Dr. Frank Cuttitta, and Dr. Kevin Camphausen (Center for Cancer Research, NCI) to assess the anti-angiogenic activity of compounds provided by NCI, both individually and in combination, as a part of this collaboration.

“Innovascreen is excited to be working with the NCI,” said Dr. John Lewis, President and CEO of Innovascreen. “Our ASET Platform allows for high-throughput, *in vivo* screening of compound libraries, a unique capability in the industry. The program will look at several individual compounds, as well as combinations of these drug candidates, to quickly and effectively determine their ability to halt or reverse new vessel growth”.

Angiogenesis, the development of new blood vessels from the existing ones, is essential for sustained tumor growth. Angiogenesis inhibitors are not toxic to most healthy cells, and seem to help some chemotherapy drugs and radiation therapy work more effectively. “Angiogenesis is a very important therapeutic target in oncology,” said Dr. Andries Zijlstra, CSO of Innovascreen.

“In collaboration with NCI, we will be able to apply the rapid and high volume throughput of our ASET platform to evaluate multiple NCI compounds. We have the unique opportunity to accurately measure the synergistic effect of novel therapeutic combinations that target distinct angiogenic mechanisms. This is something that can really only be adequately assessed in a relevant *in vivo* setting like the one our ASET platform provides.”

The ASET platform allows the screening of compounds faster and at a lesser cost than conventional animal models while providing more conclusive results. For this reason, Innovascreen is using the ASET system for *in vivo* validation of its exciting Fusogenix drug delivery platform. Innovascreen continues to develop significant data on this novel and powerful drug delivery technology for small molecules, biologics and siRNA.

About Innovascreen

With two platform technologies under management, Innovascreen is an ideal partner for an organization involved in early stage preclinical development of therapeutic candidates. The Avian System for Evaluating Therapeutics (ASET) Platform allows our clients and partners to screen compound libraries and validates lead candidates for further investment, faster, better and cheaper than other available options. Fusogenix is an advanced intracellular drug delivery platform with a unique mechanism of action that offers the chance to improve systemic delivery of therapeutic cargos. Innovascreen is a privately held company, headquartered in Nova Scotia, Canada. For more information, please visit www.innovascreen.com

Contact:

Jeff Skinner,
Director, Business Development, Innovascreen, Inc
(902) 482-3832 x 7, jeff.skinner@innovascreen.com